Published online 18 July 2008
Haematologica, Vol 93, Issue 9, 1402-1406 doi:10.3324/haematol.12982
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gertz, M. A.
Right arrow Articles by Kyle, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gertz, M. A.
Right arrow Articles by Kyle, R. A.

Multiple Myeloma

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

Morie A. Gertz, Martha Q. Lacy, John A. Lust, Philip R. Greipp, Thomas E. Witzig, Robert A. Kyle

Division of Hematology, Mayo Clinic, Rochester, MN, USA

Correspondence: Morie A. Gertz, MD, Department of Hematology, Mayo Clinic, 200 First Street SW, Rochester MN, 55905, USA. E-mail:gertz.morie{at}mayo.edu

Survival of patients with plasma cell disorders has increased. However, the expanding use of melphalan in patients with longer survival suggests that myelodysplasia may become increasingly important. The objective of this study was to determine the risk of myelodysplasia after treatment with melphalan for patients with amyloidosis. We reviewed the long-term follow-up data (more than 12 years) from 101 patients with immunoglobulin light-chain amyloidosis. We identified 10 patients with myelodysplasia or acute nonlymphocytic leukemia that directly caused death for 8 and transfusion dependency for 2. Two of the 10 patients did not have development of myelodysplasia until 144 months after first exposure to alkylating agents. The actuarial risk of myelodysplasia development at ten years was 18%. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group.

Key words: acute nonlymphocytic leukemia, amyloidosis, immunoglobulin light chain, melphalan, myelodysplasia.